Hanall announces supply agreement with Chinese firm over H1N1 vaccine

In an effort to secure an adequate supply of the vaccine, Korea's Hanall Pharmaceutical Co. signed a memorandum of understanding with Ealong Biotech Ltd., a Chinese vaccine maker, on November 11 to purchase as many as 60 million doses, enough to inoculate some 6 million people against the H1N1 virus.

Hanall said earlier in the day that it could import the vaccine into the country from the C...